drugset / Trial / NCT02396147
Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to evaluate the oral bioavailability of two new tablet formulations of TAK-385 (T4 Formulation B and T4 Formulation C) under fasted and fed conditions, relative the T2 Formulation tablet; and to estimate the effect of food on the pharmacokinetics (PK) of a single oral dose of the T4 Formulation B tablet and the T4 Formulation C tablet.
Timeline
- Start
- 2015-03
- Primary completion
- 2015-04
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relugolix | Small molecule | 120 mg | Oral |
Indications
No indication recorded.